Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 14/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2426807 | 1.00 | RET (0.51) | RETHSP90AA1HSP90AB1KMT2AL3MBTL1 | |
| SCHEMBL2426041 | 0.90 | HSP90AA1 (0.60) | RETHSP90AA1HSP90AB1 | |
| SCHEMBL2426043 | 0.90 | HSP90AA1 (0.60) | RETHSP90AA1HSP90AB1 | |
| SCHEMBL1116607 | 0.90 | HSP90AA1 (0.51) | RETHSP90AA1HSP90AB1KMT2AL3MBTL1 | |
| SCHEMBL1116609 | 0.90 | HSP90AA1 (0.51) | RETHSP90AA1HSP90AB1KMT2AL3MBTL1 | |
| SCHEMBL2098551 | 0.89 | HSP90AA1 (0.54) | RETHSP90AA1HSP90AB1JAK1 | |
| SCHEMBL2098552 | 0.89 | HSP90AA1 (0.54) | RETHSP90AA1HSP90AB1JAK1 | |
| Hydrochloric Acid SCHEMBL2427950 | 0.89 | HSP90AA1 (0.59) | RETHSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL2427947 | 0.89 | HSP90AA1 (0.59) | RETHSP90AA1HSP90AB1 | |
| SCHEMBL3980998 | 0.88 | RET (0.49) | RETHSP90AA1HSP90AB1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | RET 1262/4885HSP90AA1 1888/4885HSP90AB1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.